16 recruiting, 7 unknown, 6 not yet recruiting, 5 withdrawn. 15 Phase 2, 14 Phase 1, 8 Not applicable, 3 Early Phase 1, 2 Phase 3.
Follow CAR-T: new trials by email Literature Review of CAR-T trials Research Report on CAR-T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T in Relapsed/Refractory Multiple Myeloma CAR-T - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-08 |
| Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas Vancomycin 125mg, Radiation Therapy, CAR-T - Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL) | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 14 | 2026-05-29 | 2026-07-01 |
| Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia CAR-T - AML (Acute Myeloid Leukemia) | Phase 1 / Phase 2 | Not yet recruiting | Xuzhou Medical University | 20 | 2026-01-31 | 2026-01-27 |
| Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML CAR-T - AML (Acute Myeloid Leukemia), CAR-T | Early Phase 1 | Withdrawn | First Affiliated Hospital of Guangxi Medical University | 2026-01-05 | 2026-08-26 | |
| CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT CAR-T, DLI - B ALL, Allogenetic Hematopoietic Stem Cell Transplantation | Phase 3 | Recruiting | Peking University People's Hospital | 70 | 2025-11-30 | 2026-02-27 |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 130 | 2025-10-20 | 2026-10-05 |
| CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B-Cell | Not applicable | Recruiting | Shanxi Bethune Hospital | 15 | 2025-09-05 | 2025-02-27 |
| Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors CAR-T - Solid Tumors | Not applicable | Withdrawn | Guangzhou Bio-gene Technology Co., Ltd | 2025-08-31 | 2026-05-28 | |
| To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL CAR-T - CD7 Positive R/R PTCL | Phase 1 | Recruiting | Peking University People's Hospital | 18 | 2025-08-18 | 2025-08-27 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-06 |
| Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases CAR-T - Connective Tissue Diseases | Not applicable | Withdrawn | Guangzhou Bio-gene Technology Co., Ltd | 2025-08-07 | 2026-05-28 | |
| CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? CAR-T, ASCT - Multiple Myeloma, Newly Diagnosed | Phase 2 | Not yet recruiting | Xuzhou Medical University | 60 | 2025-07-15 | 2025-07-17 |
| A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible CAR-T - Multiple Myeloma, Newly Diagnosed | Not applicable | Not yet recruiting | Xuzhou Medical University | 35 | 2025-07-15 | 2025-07-17 |
| Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT autologous stem cell transplantation, CAR-T - Multiple Myeloma, Newly Diagnosed | Phase 2 | Not yet recruiting | Xuzhou Medical University | 60 | 2025-05-01 | 2025-05-09 |
| Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma CAR-T - Multiple Myeloma | Phase 1 | Not yet recruiting | Xuzhou Medical University | 50 | 2025-04-01 | 2025-04-06 |
| Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients CAR-T - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-03-03 | 2026-03-02 |
| Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies CAR-T - Multiple Myeloma, B-cell Lymphoma | Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | 60 | 2025-01-15 | 2025-01-06 |
| Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer CAR-T - Colorectal Cancer (CRC) | Not applicable | Withdrawn | Guangzhou Bio-gene Technology Co., Ltd | 2024-12-11 | 2026-05-28 | |
| ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT All-trans retinoic acid, zanubrutinib, radiotherapy - B-cell Non Hodgkin Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 35 | 2024-12-01 | 2024-11-01 |
| Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL zanubrutinib, CAR-T, Bridging radiotherapy - B-NHL, CART Therapy | Phase 2 | Recruiting | Ruijin Hospital | 144 | 2024-11-20 | 2025-01-24 |
Showing 20 of 39. Sign in to see all of them.
Multiple Myeloma (8) · Lymphoma, B-Cell (7) · Leukemia, Myeloid, Acute (3) · Recurrence (3) · Uterine Cervical Neoplasms (3) · Anus Neoplasms (2) · Breast Neoplasms (2) · Glioma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Oropharyngeal Neoplasms (2) · Penile Neoplasms (2) · Stomach Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2)
Xuzhou Medical University (5) · Christian Hinrichs (3) · Guangzhou Bio-gene Technology Co., Ltd (3) · Hebei Senlang Biotechnology Inc., Ltd. (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Peking University People's Hospital (2) · Ruijin Hospital (2) · The First Affiliated Hospital of Soochow University (2) · Abramson Cancer Center at Penn Medicine (1) · Beijing Boren Hospital (1) · Beijing Tiantan Hospital (1) · Bellicum Pharmaceuticals (1) · Dr. Zaineb Akram (1) · First Affiliated Hospital of Guangxi Medical University (1) · First Affiliated Hospital of Zhejiang University (1)
China (26) · United States (7) · Hong Kong (1) · Netherlands (1) · Pakistan (1)
Christian S Hinrichs, MD (3) · Kailin Xu (3) · Depei Wu, M.D (1) · Elise Chong, MD (1) · Jia Shaochang, doctor (1) · KaiLin Xu, MD. Ph.D. (1) · Kevin Curran, MD (1) · Lan He, Ph.D. degree (1) · Li Yu (1) · Maryam Khan, MBBS, MRCP (UK), FCPS(Cl Haem) (1) · Pamela Lee, MD (1) · Peijuan Ren, M.D. (1)
PMID 35432352, PMID 24311149, PMID 31219975, PMID 31335321, PMID 34025640, PMID 34113569, PMID 34464155, PMID 34777367, PMID 35338773, PMID 35488407, PMID 35798714, PMID 36059523, PMID 36131934, PMID 36477110, PMID 37774014, PMID 37883795, PMID 38049523, PMID 38712616, PMID 39620223
U01CA287904 (1)